BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $151

Benzinga Newsdesk www.benzinga.com Positive 78.3%

Neg 0% Neu 0% Pos 78.3%

BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $78 to $151.